NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

October 31, 2014

Researchers at NYU Langone Medical Center conclude new drug in development may offer first alternative to standard chemotherapy for T-Cell Acute Lymphoblastic Leukemia

August 27, 2014

A major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.

July 29, 2014

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses treatment resistance in mesothelioma.

July 29, 2014

Douglas Kondziolka, MD, MSc, director, Gamma Knife Program, vice chair, Clinical Research, Departments of Neurosurgery and Radiation Oncology, Perlmutter Cancer Center at NYU Langone, discusses updates concerning the treatment of brain metastases.

July 14, 2014

Leading experts from renowned academic centers join in one voice to encourage new perspectives in addressing brain cancer

July 14, 2014

Surgical Team at NYU Langone Medical Center Successfully Removes Life-Threatening Retroperitoneal Mass Along with Several Organs -- Staten Island Resident Expresses His Thanks

July 02, 2014

Abraham Chachoua, MD, The Jay and Isabel Fine Associate Professor of Oncology, NYU Langone Medical Center, associate director, Cancer Services, Perlmutter Cancer Center at NYU Langone, discusses ongoing clinical trials at NYU that are evaluating immunotherapy in patients with lung cancer.

June 10, 2014

Catherine M. Diefenbach, MD, assistant professor, medicine (hematology and medical oncology), Perlmutter Cancer Center at NYU Langone, explains antibody drug conjugates (ADCs)

June 04, 2014

While the combination of gemcitabine and nab-paclitaxel (Abraxane) has demonstrated survival benefits for patients with metastatic pancreatic cancer, oncologists are interested in knowing whether the regimen will transfer well into the adjuvant setting

May 30, 2014

Having a robust armamentarium to treat childhood acute lymphoblastic leukemia (ALL) is a major triumph in oncology.

May 29, 2014

Study raises concern about surgical "margins" for acral melanoma tumors, known to target the darker skins of Asians, African-Americans and Hispanics

May 28, 2014

Only a Few of More Than 109 Detected Strains Known to Cause Cancer

May 27, 2014

Nagashree Seetharamu, MD, assistant professor, Medicine (Hematology and Medical Oncology), Perlmutter Cancer Center at NYU Langone, discusses the possibility of using immunotherapy agents to treat head and neck cancers.

May 22, 2014

Part of the Medical Center's Commitment to a "Supportive Oncology" Approach to Cancer Treatment

March 24, 2014

Leader in Supportive Oncology at Perlmutter Cancer Center at NYU Langone Medical Center to Take Leadership Position with the American College of Physicians.

February 21, 2014

Komal L. Jhaveri, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses T-DM1 for neoadjuvant breast cancer treatment.

February 04, 2014

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses two trials that evaluate the efficacy of bevacizumab in bladder cancer.

January 21, 2014

Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, describes the mechanism and utility of Samsca (tolvaptan).

January 07, 2014

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses using Doxil to treat ovarian cancer.

November 25, 2013

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the potential of immunotherapy agents as treatment for bladder cancer.